At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 203 enrolled
Drug / intervention
Olorofimdrug
Likely dose
Olorofim 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options
In Brief
A Phase 2 clinical trial evaluating Olorofim for Invasive Fungal Infections. Completed, enrolled 203 participants across 82 sites in 17 countries.
Detailed Summary
A study to evaluate olorofim (F901318) for the treatment of invasive fungal infections in participants lacking suitable alternative treatment options.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInvasive Fungal Infections
CountriesAustralia, Belgium, Brazil, Egypt, France, Germany, Israel, Netherlands, Poland, Russia, South Korea, Spain, Thailand, Turkey (Türkiye), United Kingdom, United States, Vietnam
CollaboratorsIQVIA Pty Ltd
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartJun 2018
First PostedJul 2018
Primary CompletionFeb 2023
TodayJul 2026
First PostedJul 11, 2018
Enrollment StartJun 6, 2018
Primary CompletionFeb 10, 2023
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 8.0 years ago
Interventions
Olorofimdrug
30mg oral tablets